TESERPATUREV
UNII 6S57D3Y2F5

Substance Identification & Data

This profile provides standardized clinical and technical data for Teserpaturev, uniquely identified by the FDA Unique Ingredient Identifier (UNII) 6S57D3Y2F5.

Technical mappings include the Chemical Abstracts Service (CAS) Registry Number 1802360-34-4 and the RxNorm Concept ID (RxCUI) N/A. Explore the sections below for detailed nomenclature and a complete directory of NDC-listed products containing this ingredient.

FDA UNII Code

6S57D3Y2F5

CAS Registry Number

1802360-34-4

RxNorm Concept ID

N/A

Detailed Substance Profile

Preferred Name

TESERPATUREV

Official standardized name for this substance within the FDA UNII nomenclature system.

NCI Thesaurus

C190358

National Cancer Institute reference terminology for clinical and research data.

INN ID

10794

Sequential identifier assigned via the WHO International Nonproprietary Name program.

Substance Type

structurallyDiverse

ISO 11238 classification category (e.g., Chemical, Polymer, Protein).

Synonyms and Nomenclature

This section provides a complete list of nomenclature and identifier mappings for Teserpaturev. Identifiers are organized into official regulatory terms, commercial trade names, and technical systematic synonyms used to ensure accurate identification across clinical pharmaceutical databases, regulatory filings, and electronic health records.

FDA Official Name

TESERPATUREV

Common Names & Synonyms

A CONDITIONALLY-REPLICATING ONCOLYTIC HERPES SIMPLEX VIRUS TYPE 1 (HSV-1) STRAIN F THAT HAS GENETICALLY ENGINEERED DELETIONS WITHIN BOTH COPIES OF THE .GAMMA.34.5 GENE AND WITHIN THE .ALPHA.47 GENE, AND FURTHER MODIFIED BY INSERTION OF AN EXPRESSIBLE BETA-GALACTOSIDASE (LACZ) GENE IN THE ICP6 LOCUS

AN ONCOLYTIC HERPES SIMPLEX VIRUS-1 VECTOR CONTAINING MUTATIONS .GAMMA.34.5, ICP6 AND .ALPHA.47 WITH SELECTIVE TOXICITY TO TUMOR CELLS

TESERPATUREV [INN]

TESERPATUREV [WHO-DD]